Pangolin Therapeutics

Executive Summary

Pangolin Therapeutics is a preclinical biotech pioneering small-molecule drugs against intrinsically disordered proteins (IDPs), which lack stable binding pockets and have been historically undruggable. Founded in 2020 in Cambridge, MA, the company targets IDPs implicated in major diseases: IAPP in type 2 diabetes, alpha-synuclein in Parkinson's, and Myc in various cancers. By leveraging a proprietary platform to identify compounds that modulate IDP misfolding and aggregation, Pangolin aims to open a new therapeutic frontier. The company operates at the intersection of oncology and immunology, with potential applications beyond its initial indications. While still in early stages with no disclosed pipeline, its novel approach could address significant unmet needs, though technical challenges remain high. The company's progress in advancing lead programs toward IND-enabling studies will be critical to validating its platform and attracting further investment.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing70% success
• Q1 2027Lead Optimization Data for Myc Program50% success
• H2 2026Partnership with Academic or Pharma Collaborator40% success